SOURCE: Vicor Technologies, Inc.

Vicor Technologies, Inc.

December 21, 2010 08:30 ET

Dr. Mitchell Karl to Join Vicor Technologies' Scientific Advisory Board and Serve as Associate Medical Director

BOCA RATON, FL--(Marketwire - December 21, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Mitchell Scott Karl, MD, will join the Company's Scientific Advisory Board and serve as the Company's Associate Medical Director, a new part-time position. Vicor Technologies, Inc. (OTCBB: VCRT) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

"Dr. Karl is a well-respected cardiologist and clinical professor whose experience and knowledge has been an asset to Vicor since he became a consultant to the Company earlier this year. We are extremely gratified to now have him serving as our Associate Medical Director on a part-time basis and as a member of our Scientific Advisory Board," stated Mr. Fater.

As Associate Medical Director, Dr. Karl will assist Dr. Daniel Weiss, Vicor's Chief Medical Officer, in developing the direction of the Company's future scientific focus and adapting that science for clinical use. He will also serve as an additional liaison, in conjunction with CEO David Fater, to the U.S. Food and Drug Administration, potential partner companies, and Vicor's clinical research organization. Additionally, Dr. Karl will assist in the oversight of Vicor's medical and clinical operations, and review/evaluate for publication all pertinent medical manuscripts and publications. Dr. Karl will also assist Dr. Edward Lundy, newly-named Chairman of the Scientific Advisory Board, as needed, with his responsibilities, which include interacting with Vicor's researchers and marketers to help identify new markets for the Company's products and serve, in conjunction with Dr. Weiss, as a spokesperson on medical affairs related to Vicor's target markets. Vicor's Scientific Advisory Board is composed of professionals in the medical, academic, and life sciences arenas. 

Dr. Mitchell Scott Karl is a Boca Raton-based cardiologist and a staff cardiologist at Boca Raton Community Hospital. He is also Clinical Associate Professor of Biomedical Science at Florida Atlantic University. He has served on the staffs of Holy Cross Hospital and North Ridge Medical Center in Fort Lauderdale, West Boca Medical Center in Boca Raton, and Delray Medical Center in Delray Beach. Additionally, he was Clinical Associate Professor and, earlier, Clinical Assistant Professor of Pharmacy Practice at Nova Southeastern University. Dr. Karl served his internship, residency and cardiology fellowship training at Montifiore Medical Center of the Albert Einstein College of Medicine. Dr. Karl earned his MD at Downstate Medical Center. He holds an Executive MBA in Medical Management from Nova Southeastern Graduate School and a BA in Psychology, Summa Cum Laude, from Emory University.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at

The appearance of name-brand institutions, such as the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i®values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) to be used in patients undergoing cardiovascular disease testing and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-28

Contact Information